BPC-157 · Sermorelin · Ipamorelin · CJC-1295 · TB-500 · GHK-Cu

Peptide Marketing Agency

We're the creative team that produces the ads your media buyer tests. Peptide therapy advertising is in a gray zone right now — and the July 2026 PCAC hearing may change what you can say overnight. We build the creative library before that window closes.

Get in Touch

We plug into your media buyer. We don't replace them.

Peptide advertising exists in a regulatory gray zone that's about to get a lot more defined.

Peptide therapy is one of the fastest-growing categories in telehealth — and one of the most difficult to advertise. Platform policies haven't caught up to the category. Some compounds are prescribed by physicians through compounding pharmacies; others are sold as research chemicals; others occupy an ambiguous middle ground. The advertising rules for each are genuinely different, and most creative teams don't know the difference.

The July 2026 PCAC (Pharmacy Compounding Advisory Committee) hearing is expected to address the classification of several commonly prescribed peptides. If key compounds are reclassified, the advertising rules that apply to them change — and brands that haven't built a compliant creative library in advance will be scrambling.

The brands winning in peptide advertising right now are the ones building creative that's specific enough to convert but constructed to survive a regulatory reclassification. That requires a creative team who understands both the compounds and the compliance framework around them.

Creative built for the peptide category — before the rules get tighter.

Six creative formats built for the regulatory and psychographic realities of peptide therapy advertising.

Licensed Medical Professional Formats

MD, PA, or NP on camera discussing peptide mechanisms and clinical use cases. These formats survive platform review because they're physician-sourced, educational, and don't make therapeutic claims on behalf of the brand.

Personal Experience Creator Content

Creators who have used specific peptides (BPC-157 for recovery, sermorelin for growth hormone support, GHK-Cu for skin) documenting their experience without making therapeutic claims. The framing is personal observation, not medical advice.

Recovery and Performance Angles (BPC-157, TB-500)

Athletic recovery, injury support, training adaptation. Framed around the consultation process and physician supervision rather than direct outcome claims.

Longevity and Vitality Angles (Sermorelin, Ipamorelin, CJC-1295)

Growth hormone secretagogue therapy for body composition, sleep quality, and recovery. Positioned as an optimization protocol under physician oversight.

Skin and Tissue Regeneration (GHK-Cu, MK-677)

Beauty-adjacent and wellness-forward framing for peptides with skin and connective tissue applications. Distinct from the performance/recovery category in buyer profile and creative approach.

Before-PCAC Creative Library Build

A strategic argument for building a deep creative library now, before the July 2026 hearing potentially restricts claims further. Early movers will have tested creative and performance data; late movers will be starting from scratch in a tighter environment.

Creator Types

Gray-market peptide users with documented, long-form experience. Licensed medical professionals (MD/PA/NP) with peptide prescription experience. Performance athletes and wellness practitioners with credible category standing.

Peptide advertising operates under four concurrent regulatory pressures — and one approaching deadline.

PCAC July 2026 Hearing

The FDA's Pharmacy Compounding Advisory Committee is scheduled to review classification of several commonly prescribed peptides. Reclassification could change which compounds can be advertised as compounded medications and what claims are permissible. We track this and build creative designed to survive reclassification.

"Research Peptide" Framing Risks

Some brands position peptides as "research use only" to sidestep medical claims requirements. This framing carries its own legal risks — and Meta doesn't treat it as a safe harbor. We avoid this framing and build legitimate physician-supervised treatment creative instead.

No Therapeutic Claims Without Approval

BPC-157, TB-500, and most growth hormone secretagogues are not FDA-approved drugs. Any ad that makes a therapeutic claim ("heals tendons," "restores growth hormone levels") for a non-approved compound is making an unapproved drug claim. We frame creative around the consultation process and physician oversight, not compound-specific therapeutic outcomes.

Platform Supplement vs. Drug Category

How a platform classifies a peptide affects which policies apply. We build creative that's constructed to pass supplement category review without making it sound like a supplement — because the consultation model is the actual differentiator.

State Compounding Pharmacy Rules

The rules for what compounding pharmacies can produce and ship vary by state. Our creative doesn't make jurisdiction-specific availability claims that don't apply universally.

Creator and Endorser Disclosure

Any creator receiving product or compensation must disclose. For peptides specifically, we also ensure creator content is framed as personal experience rather than advice or recommendation.

$50M+

Creative managed across telehealth brands

100M+

Organic views generated from our creative

2,500+

Ads produced across GLP-1, TRT, ED, hair loss, peptides

How It Works

Four steps from brief to your media buyer's dashboard.

Strategy Call

We audit your current creative approach, map your buyer's angles, and identify the gaps your media buyer needs filled.

Creative Brief

We develop the angles, hooks, and creator profiles. You approve the strategy before a single frame is shot.

Production

We source the right creators, direct and produce the content, and review every script against FDA, FTC, and platform policies.

Delivered to Your Media Buyer

We hand over a complete batch of tested creative assets. Your media buyer runs the ads. They report back top performers. We iterate.

Frequently Asked Questions

What's actually legal to advertise in the peptide space right now?

The honest answer is that it depends on the specific compound and how you frame it. Peptides prescribed through compounding pharmacies under physician supervision can be advertised through the consultation model — you're marketing access to a physician who may prescribe the compound, not the compound itself. We build creative that advertises the clinical process rather than the therapeutic outcome of the peptide. See /blog/telehealth-advertising-compliance/peptide-advertising-facebook for current platform-specific guidance.

What is the PCAC hearing and should I be worried?

The Pharmacy Compounding Advisory Committee (PCAC) is an FDA advisory body that periodically reviews which bulk drug substances can be used in compounding. A July 2026 hearing is expected to address several peptides currently popular in telehealth. Reclassification doesn't automatically ban advertising, but it changes the compliance framework significantly. We advise brands to build and test a creative library now while the current framework is in place. See /blog/telehealth-ugc-ads/ugc-peptide-creators-telehealth for more context.

How do you find creators who actually use peptides?

We maintain relationships with a creator network that has documented experience with specific compounds — primarily through the performance, recovery, and longevity communities. For physician-authority formats, we work with MDs and PAs who prescribe peptide protocols clinically. The key is that we brief them with specific compliance guardrails before they produce any content: personal experience framing, no therapeutic claims, clear disclosure of any compensated relationship.

Who runs our peptide ads — your team or our media buyer?

Your media buyer runs the ads. We produce them. This model is especially important in the peptide space because platform review can be unpredictable — you want a media buyer who understands your account history and risk tolerance making real-time decisions about which creative to run, not a creative team making those calls from a distance.

Should we build a creative library before the PCAC hearing?

If you're operating in the peptide space, yes. Performance data on creative is valuable — it takes testing to know what converts. Brands that build and test a creative library before any potential reclassification will have a significant advantage over brands that wait. See /blog/telehealth-ad-creative/peptide-ad-creative-telehealth for the specific formats and angles that are working in this category now.

YOUR MEDIA BUYER NEEDS CREATIVE. WE BUILD IT.

Book a strategy call. We'll map out exactly what creative your media buyer needs to test next — and what a full production batch looks like for your vertical.

Get in Touch

Or email us at sales@telehealthmedia.com